Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Pfizer SA

Home Clinical Trial Sponsors and OrganizationsPfizer SA

Pfizer SA

ACTIVE

Av. Libertador, Caracas, Distrito Federal, VenezuelaSubsidiary

Part of PFIZER INC.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

119

56 active

Approvals

8

Total approvals

Agencies

2

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Not Applicable

64

53.8%

Phase 1

37

31.1%

Trial Status Distribution

Active, not recruiting

55

46.2%

Completed

56

47.1%

Not yet recruiting

1

0.8%

Recruiting

1

0.8%

Clinical Trials

Trials sponsored by this organization (119)

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG- TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE

Apr 201637 participants

A Phase 3 Randomized, Double-Blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Pacitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer.

Not yet recruiting

A PHASE 3B/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OFTOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TOADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELYTO SEVERELY ACTIVE RHEUMATOID ARTHRITIS

May 201517 participants

A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTSWITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA

May 20155 participants

A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

Dec 20148 participants

PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS

Nov 2014190 participants

AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008

Jul 20142 participants

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) IN ADULTS WITH TYPE 2 DIABETESAND OVERT NEPHROPATHY

Dec 201310 participants

Page 1 of 15

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

2

Approvals

SFDA

Saudi Food and Drug Authority

6

Approvals

Recent Approvals

PROSTIN E2 2MG VAGINAL GEL IN APPLICATOR

PROSTIN E2 VAGINAL TAB. 3MG

GENOTROPIN 16IU CARTRIDGE

PROSTIN E2 1MG VAGINAL GEL IN APPLICATOR

GENOTROPIN GOQUICK 12MG PRE-FILLED PEN

Genotropin GoQuick 5.3 mg

Methylprednisolone Sodium Succinate for Injection

Methylprednisolone Sodium Succinate for Injection

News

No news articles found

On this page

Overview
Clinical Trials119
Approvals8
News

Back to Organizations